Biohaven reports Q1 non-GAAP EPS ($1.64), consensus ($1.47)

Cash, cash equivalents, marketable securities and restricted cash as of April 30, 2025 totaled approximately $518M. In addition, the company received $250M in gross proceeds in April 2025 from Oberland Capital. CEO Vlad Coric commented, “In spite of a challenging macroeconomic climate and economic uncertainty, our team has remained more focused than ever on strategic execution and creating a strong financial balance sheet to create value across our broad portfolio of innovative product candidates…we eagerly await the completion of the NDA review for troriluzole and continued advancement of our MoDE and TRAP degraders into the clinic. We expect to complete three separate Phase 1 studies in 1H 2025 with three innovative compounds…and are advancing four additional degrader molecules in parallel. We also look forward to delivering key clinical readouts…in 2H 2025. In oncology, interim Phase 1 data remain on track for 2025 with our lead clinical Trop-2 antibody drug conjugate program, BHV-1510, and initiation of a Phase 1 study with the field’s first FGFR3 ADC, BHV-1530, for patients with urothelial cancer & other tumors…we are also extremely excited about BHV-8000, our TYK2/JAK1 inhibitor, and eagerly anticipate initiating our Phase 2/3 study in Parkinson’s disease in 1H 2025. In addition, our recent $600M financing agreement with Oberland Capital will provide financial flexibility to advance our troriluzole commercialization plans, accelerate clinical development and operational execution across our five platforms, and be ready to execute on strategic opportunities as they arise…”